Table 2 Demographic, clinical and laboratory data of ALS patients from Halle and Milan (n = 130)
Age (years) at blood collection mean ± SD | 63.24 ± 10.50 |
Female % | 41 (31.6) |
BMI mean ± SD | 24.12 ± 3.73 |
Site of symptom onset N (%) | |
Bulbar | 27 (20.8) |
Spinal: upper limbs, trunk, lower limbs | 98 (75.4): 49 (37.7), 3 (2.3), 46 (35.4) |
Generalised | 4 (3.1) |
Cognitive | 1 (0.7) |
Disease duration at blood collection (months) mean ± SD | 21.82 ± 20.33 |
Clinical phenotype N(%) | |
Classic | 83 (63.9) |
Bulbar | 16 (12.3) |
UMN-predominant | 9 (6.9) |
LMN-predominant | 22 (16.9) |
Diagnosis according to revised El Escorial criteria | |
Definite | 31 (23.8) |
Probable | 30 (23.1) |
Probable laboratory supported | 46 (35.4) |
Possible | 23 (17.7) |
King’s staging system | |
1 | 4 (3.1) |
2 | 65 (50.0) |
3 | 46 (35.4) |
4 | 15 (11.5) |
ALSFRS-R score mean ± SD | 38.54 ± 8.17 |
Disease progression rate at blood sampling mean ± SD | 0.71 ± 0.62 |
ECAS total score mean ± SD | 100.57 ± 17.58 |
Blood Creatine Kinase (U/L) Median (IQR) (normal values < 171 U/L) % of cases with normal values | 133.0 (65.9-253.4) 59.3 |
Blood Troponin T (ng/L) Median (IQR) (normal values < 14 ng/L) % of cases with normal values | 51.0 (16.9-74.3) 19.2 |
Blood Myoglobin (µg/L) Median (IQR) (normal values 25-72 µg/L) % of cases with normal values | 43.0 (30.6-89.5) 70.6 |
